7.98

2.84% 0.22

After Hours: 7.90 -0.08 -1.00%

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $7.98, with a volume of 856.89K. It is up +2.84% in the last 24 hours and down -1.54% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Previous Close:

$7.76

Open:

$7.83

24h Volume:

856.89K

Relative Volume:

0.56

Market Cap:

$658.93M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-2.5253

EPS:

-3.16

Net Cash Flow:

$-176.27M

1W Performance:

+15.15%

1M Performance:

-1.54%

6M Performance:

+52.00%

1Y Performance:

-42.13%

1-Day Range:

$7.54

$8.08

1-Week Range:

$7.12

$8.08

52-Week Range:

$2.68

$14.80

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

479

Twitter

@Replimune

Next Earnings Date

2025-02-11

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	7.98	640.76M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-25	Upgrade	BMO Capital Markets	Underperform → Market Perform
Oct-27-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-20-25	Upgrade	JP Morgan	Underweight → Neutral
Oct-20-25	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Oct-20-25	Upgrade	Wedbush	Neutral → Outperform
Sep-19-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

11:13 AM

Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know - Finviz

11:13 AM

08:31 AM

Buybacks Report: Can Replimune Group Inc expand its profit marginsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

08:31 AM

02:24 AM

How Replimune Group Inc. stock reacts to job market dataTrade Entry Report & Daily Growth Stock Investment Tips - mfd.ru

02:24 AM

Feb 11, 2026

Insider Sell: Is Replimune Group Inc stock undervalued right now2025 Market Outlook & Daily Growth Stock Investment Tips - baoquankhu1.vn

Feb 11, 2026

Feb 08, 2026

Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st

Feb 08, 2026

Feb 05, 2026

Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00 - MarketBeat

Feb 05, 2026

Piper Sandler Maintains 'Overweight' Rating for REPL, Raises PT to $14 | REPL Stock News - GuruFocus

Feb 05, 2026

Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire

Feb 05, 2026

Replimune Secures Financial Runway Through 2027 - AD HOC NEWS

Feb 05, 2026

Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Feb 05, 2026

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Feb 05, 2026

Feb 04, 2026

Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price - MarketBeat

Feb 04, 2026

RP1 melanoma setback and SEC probe weigh on Replimune (NASDAQ: REPL) - Stock Titan

Feb 03, 2026

Earnings Breakdown: Replimune Group Q3 - Benzinga

Feb 03, 2026

Replimune Group Signs Loan and Security Agreement Amendment With Hercules Capital - TradingView

Feb 03, 2026

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Feb 03, 2026

Replimune Group, Inc. Enters into Third Amendment to Loan and Security Agreement with Hercules Capital, Inc - marketscreener.com

Feb 03, 2026

Jan 30, 2026